Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.44) by 34.09 percent. This is a 81.39 percent increase over losses of $(3.17) per share from the same period last year.
Analyst Ups Zscaler’s Price Target On Record Pipeline And Rebounding Federal Business
Stifel analyst Adam C. Borg reiterated a Buy rating on the shares of Zscaler, Inc. (NASDAQ:ZS), raising the price target to $150…